Home Cart Sign in  
Chemical Structure| 487021-52-3 Chemical Structure| 487021-52-3

Structure of AR-A014418
CAS No.: 487021-52-3

Chemical Structure| 487021-52-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AR-A014418 is a selective inhibitor of GSK3β with IC50 of 104 ± 27 nM.

Synonyms: GSK 3β inhibitor VIII; AR 0133418; GSK-3beta Inhibitor VIII.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AR-A014418

CAS No. :487021-52-3
Formula : C12H12N4O4S
M.W : 308.31
SMILES Code : O=C(NC1=NC=C([N+]([O-])=O)S1)NCC2=CC=C(OC)C=C2
Synonyms :
GSK 3β inhibitor VIII; AR 0133418; GSK-3beta Inhibitor VIII.
MDL No. :MFCD08277040
InChI Key :YAEMHJKFIIIULI-UHFFFAOYSA-N
Pubchem ID :448014

Safety of AR-A014418

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of AR-A014418

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

Target
  • GSK-3β

    GSK-3β, Ki:38 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Hippocampal neurons 10 µM 1 hour AR-A014418 significantly inhibited AMPA-induced GluR1 receptor internalization by 48%. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11573-8.
A375 20 µM 12 hours To detect the effect of AR-A014418 on PD-L1 expression, it was found that AR-A014418 inhibited PD-L1 expression. J Immunother Cancer. 2023 May;11(5):e006483.
Hela 40 µM 16 hours To detect the effect of AR-A014418 on PD-L1 expression, it was found that AR-A014418 inhibited PD-L1 expression. J Immunother Cancer. 2023 May;11(5):e006483.
IEC-6 cells 10 µM 24 hours To investigate the effect of AR-A014418 on the migration of IEC-6 cells, results showed that AR-A014418 inhibited cell migration under all conditions. Cell Mol Life Sci. 2006 Dec;63(23):2871-9.
NRCMs 1 µM 24 hours To study the function of eEF2K in DIC, it was found that eEF2K overexpression alleviated DOX-induced cardiomyocyte injury and atrophy Cell Biol Toxicol. 2024 Dec 21;41(1):15.
22Rv1 0.25 µM 30 hours AR-A014418 activates AR in the absence of androgens, increasing AR reporter gene activity. 2008 Jun;10(6):624-34. doi: 10.1593/neo.08248.
PC3 0.5 µM 4 hours AR-A014418 stimulates nuclear translocation of AR in the absence of androgens. 2008 Jun;10(6):624-34. doi: 10.1593/neo.08248.
LUHMES cells 2 µM 6 hours To measure the effect of GSK-3 inhibitors on tau phosphorylation, results showed that AR-A014418 at 2 µM did not significantly reduce tau phosphorylation levels. Br J Pharmacol. 2007 Nov;152(6):959-79.
LNCaP 0.25 µM 96 hours AR-A014418 stimulates the proliferation of LNCaP cells in the absence of androgens. 2008 Jun;10(6):624-34. doi: 10.1593/neo.08248.
Primary cultured neurons 33 µM Inhibition of GSK-3β significantly reduced the levels of full-length fractalkine in total cell extracts, mainly affecting the plasma membrane-associated form of the protein. Cell Mol Life Sci. 2017 Mar;74(6):1153-1163.
HEK293 cells 33 µM GSK-3β inhibition led to decreased levels of fractalkine at the plasma membrane, which in turn reduced the levels of soluble fractalkine. Cell Mol Life Sci. 2017 Mar;74(6):1153-1163.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Seipin-nKO mice Intraperitoneal injection 1 mg/kg Once daily for 28 days AR-A014418 treatment partially reduced the level of cleaved caspase-3 and alleviated the deficits in motor coordination. Cell Death Dis. 2018 May 1;9(5):440
C57BL/6 mice 5-HT2A receptor function model Intraperitoneal injection 10 or 20 mg/kg Single administration To test the effect of AR-A014418 on DOI-induced head-twitch response (HTR) and ear-scratch response (ESR). Results showed that AR-A014418 did not significantly affect the DOI-induced HTR or ESR. Br J Pharmacol. 2018 Jul;175(13):2599-2610
C57BL/6 mice Acute DIC model Intraperitoneal injection 15 mg/kg Single injection, lasting 5 days To study the role of eEF2K in DIC, it was found that eEF2K overexpression alleviated DOX-induced cardiac dysfunction and myocardial mass loss Cell Biol Toxicol. 2024 Dec 21;41(1):15.
Rabbit Preterm rabbit model of intraventricular hemorrhage Intramuscular injection 20 mg/kg Twice a day for seven days GSK-3 β inhibition accelerated OPC maturation, myelination, and neurological recovery, and reduced microglia infiltration and IL1 β expression Neurobiol Dis. 2018 Oct;118:22-39
Rats 12-day old postnatal rat model Oral 30 mg/kg Single dose, duration of 2, 4, 6 hours To evaluate the effect of AR-A014418 on tau phosphorylation in vivo, results showed that AR-A014418 did not significantly reduce tau phosphorylation levels in the cortex or hippocampus at any time point. Br J Pharmacol. 2007 Nov;152(6):959-79.
Mice Tail suspension test and forced swim test 30 μmol/kg 14 days AR-A014418 enhanced surface GluR1 levels in the hippocampal region and showed antidepressant-like effects in the tail suspension and forced swim tests. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11573-8.
Rats Hindlimb suspension model Intraperitoneal injection 4 mg/kg Once daily for 7 days To investigate the effect of AR-A014418 on ribosome biogenesis and protein synthesis rates in rat soleus muscle under hindlimb suspension conditions. Results showed that AR-A014418 partially attenuated the unloading-induced decline in markers of ribosome biogenesis and protein synthesis rates. Int J Mol Sci. 2022 Mar 2;23(5):2751

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.24mL

0.65mL

0.32mL

16.22mL

3.24mL

1.62mL

32.43mL

6.49mL

3.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories